Frank Wang
Boston University(US)Sun Yat-sen University(CN)University of Michigan(US)PTC (United States)(US)Swedish Medical Center(US)Michigan United(US)Michigan Medicine(US)HealthONE(US)Sun Yat-sen University Cancer Center(CN)Massachusetts Institute of Technology(US)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Dermatologic Treatments and Research, Lung Cancer Treatments and Mutations, Chronic Myeloid Leukemia Treatments, Fibroblast Growth Factor Research
Most-Cited Works
- → AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance(2009)1,234 cited
- → Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris(2004)890 cited
- → In Vivo Stimulation of De Novo Collagen Production Caused by Cross-linked Hyaluronic Acid Dermal Filler Injections in Photodamaged Human Skin(2007)517 cited
- → The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B.(1992)412 cited
- → Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase(2016)396 cited
- → Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant